NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$6.62

+0.08 (+1.22 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.47

▼

$6.67

50-Day Range

$6.52

▼

$7.85

52-Week Range

$4.80

▼

$10.67

Volume53,181 shs

Average Volume130,165 shs

Market Capitalization$172.14 million

P/E RatioN/A

Dividend YieldN/A

Beta0.07

30 days | 90 days | 365 days | Advanced Chart

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Down 50.4% in June
July 19, 2021 | americanbankingnews.com

Short Interest in Fennec Pharmaceuticals Inc (NASDAQ:FENC) Declines By 50.4%
July 17, 2021 | americanbankingnews.com

We're Hopeful That Fennec Pharmaceuticals (NASDAQ:FENC) Will Use Its Cash Wisely
July 15, 2021 | nasdaq.com

Analysts Expect Fennec Pharmaceuticals Inc (NASDAQ:FENC) Will Post Earnings of -$0.19 Per Share
July 8, 2021 | americanbankingnews.com

Fennec Pharma Resubmits NDA For Pedmark
May 28, 2021 | nasdaq.com

Why Fennec Pharmaceuticals's Stock is Trading Higher Today
April 21, 2021 | msn.com

Analysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
April 4, 2021 | finance.yahoo.com

What Type Of Shareholders Make Up Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Registry?
February 3, 2021 | finance.yahoo.com

Fennec Pharmaceuticals EPS misses by $0.05
November 16, 2020 | seekingalpha.com

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
Previous Symbol
CUSIPN/A
CIK1211583
Webwww.fennecpharma.com
Phone919-636-4530
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales1,012.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.12 per share
Price / Book5.91

Profitability

EPS (Most Recent Fiscal Year)($0.76)
Net Income$-18,110,000.00
Net MarginsN/A
Return on Equity-62.70%
Return on Assets-57.35%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares26,003,000
Market Cap$172.14 million
Next Earnings Date8/4/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

810th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

118th out of 213 stocks

3.5 Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.50, Fennec Pharmaceuticals has a forecasted upside of 104.2% from its current price of $6.61.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Fennec Pharmaceuticals has received 171 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Fennec Pharmaceuticals has received 85 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Fennec Pharmaceuticals has received 66.80% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote “Outperform” if you believe FENC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.68% of the stock of Fennec Pharmaceuticals is held by insiders.
Percentage Held by Institutions
55.28% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to decrease in the coming year, from $0.49 to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -8.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -8.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fennec Pharmaceuticals has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Fennec Pharmaceuticals?

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 703,700 shares, a decline of 50.4% from the June 15th total of 1,420,000 shares. Based on an average daily volume of 167,700 shares, the short-interest ratio is currently 4.2 days. Currently, 3.3% of the shares of the stock are short sold.
View Fennec Pharmaceuticals' Short Interest.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Thursday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.03.
View Fennec Pharmaceuticals' earnings history.

How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FENC stock has decreased by 0.2% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for FENC?

4 brokerages have issued 1 year price objectives for Fennec Pharmaceuticals' stock. Their forecasts range from $11.00 to $17.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 103.9% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:

Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
Mr. Mark Gowland, Controller
Mr. Lei Fang, Pres of Pharstat Inc
Ms. Anne McKay, Regulatory Consultant (Age 64)

Who are some of Fennec Pharmaceuticals' key competitors?

Some companies that are related to Fennec Pharmaceuticals include Passage Bio (PASG), Taysha Gene Therapies (TSHA), Curis (CRIS), Osiris Therapeutics (OSIR), Molecular Partners (MOLN), Finch Therapeutics Group (FNCH), MeiraGTx (MGTX), Cellectis (CLLS), Aligos Therapeutics (ALGS), DBV Technologies (DBVT), Precision BioSciences (DTIL), Acumen Pharmaceuticals (ABOS), Talaris Therapeutics (TALS), Adaptimmune Therapeutics (ADAP) and Poseida Therapeutics (PSTX).
View all of FENC's competitors.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $6.62.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of $172.14 million and generates $170,000.00 in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here